Validation of the Recap of Atopic Eczema (RECAP) Measurement Instrument for Eczema Control in Adult Patients in an Asian Clinical Setting
DOI:
https://doi.org/10.2340/actadv.v104.32323Keywords:
atopic eczema, outcomes, measurementAbstract
Recap of atopic eczema (RECAP) is a self-reported 7-item questionnaire recommended by the Harmonising Outcome Measures in Eczema initiative to measure eczema control. As RECAP has not been validated in a real-world clinical population in Asia, RECAP was investigated as a measure of eczema control in Singapore. Patients with atopic eczema at the National Skin Centre from July 2019 to January 2020 were included for analysis. Both patient- and physician-reported outcome measures were available for correlation analyses. Correlation analysis was also performed to investigate construct validity, and floor or ceiling effects of RECAP. A total of 260 atopic eczema patients aged between 15 and 87 years were recruited. There were minimal floor and ceiling effects for RECAP scores. There were strong, significant correlations of RECAP with POEM (r = 0.84, p < 0.001) and DLQI (r = 0.81, p < 0.001). Correlation with SCORAD was moderate (r = 0.60, p < 0.001). Correlations remained similar after age, gender, and ethnicity adjustments. Discriminative validity was demonstrated by a significant linear trend of increasing RECAP scores with increasing eczema severity. RECAP demonstrates good discriminative and construct validity evidenced by strong correlations with symptoms and quality of life and moderate correlations with eczema signs. RECAP is useful to measure eczema control in Singapore.
Downloads
References
McNally N, Phillips D. Geographical epidemiology of atopic dermatitis. Cambridge: Cambridge University Press; 2000.
https://doi.org/10.1017/CBO9780511545771.007 DOI: https://doi.org/10.1017/CBO9780511545771.007
Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113: 832-836.
https://doi.org/10.1016/j.jaci.2003.12.591 DOI: https://doi.org/10.1016/j.jaci.2003.12.591
Eyerich K, Eyerich S. Immune response patterns in non-communicable inflammatory skin diseases. J Eur Acad Dermatol Venereol 2018; 32: 692-703.
https://doi.org/10.1111/jdv.14673 DOI: https://doi.org/10.1111/jdv.14673
Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441-446.
https://doi.org/10.1038/ng1767 DOI: https://doi.org/10.1038/ng1767
Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers 2018; 4: 1.
https://doi.org/10.1038/s41572-018-0001-z DOI: https://doi.org/10.1038/s41572-018-0001-z
Weisshaar E, Diepgen TL, Bruckner T, Fartasch M, Kupfer J, Lob-Corzilius T, et al. Itch intensity evaluated in the German Atopic Dermatitis Intervention Study (GADIS): correlations with quality of life, coping behaviour and SCORAD severity in 823 children. Acta Derm Venereol 2008; 8: 234-239.
https://doi.org/10.2340/00015555-0432 DOI: https://doi.org/10.2340/00015555-0432
Ring J, Zink A, Arents BWM, Seitz IA, Mensing U, Schielein MC, et al. Atopic eczema: burden of disease and individual suffering - results from a large EU study in adults. J Eur Acad Dermatol Venereol 2019; 33: 1331-1340.
https://doi.org/10.1111/jdv.15634 DOI: https://doi.org/10.1111/jdv.15634
Blome C, Radtke MA, Eissing L, Augustin M. Quality of life in patients with atopic dermatitis: disease burden, measurement, and treatment benefit. Am J Clin Dermatol 2016; 17: 163-169.
https://doi.org/10.1007/s40257-015-0171-3 DOI: https://doi.org/10.1007/s40257-015-0171-3
Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol 2018; 121: 340-347.
https://doi.org/10.1016/j.anai.2018.07.006 DOI: https://doi.org/10.1016/j.anai.2018.07.006
Burke LB, Kennedy DL, Miskala PH, Papadopoulos EJ, Trentacosti AM. The use of patient-reported outcome measures in the evaluation of medical products for regulatory approval. Clin Pharmacol Ther 2008; 84: 281-283.
https://doi.org/10.1038/clpt.2008.128 DOI: https://doi.org/10.1038/clpt.2008.128
Bozek A, Reich A. Assessment of intra- and inter-rater reliability of three methods for measuring atopic dermatitis severity: EASI, objective SCORAD, and IGA. Dermatology 2017; 233: 16-22.
https://doi.org/10.1159/000472711 DOI: https://doi.org/10.1159/000472711
Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol 2004; 140: 1513-1519.
https://doi.org/10.1001/archderm.140.12.1513 DOI: https://doi.org/10.1001/archderm.140.12.1513
Schmitt J, Langan S, Williams HC, European Dermato-Epidemiology Network. What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol 2007; 120: 1389-1398.
https://doi.org/10.1016/j.jaci.2007.08.011 DOI: https://doi.org/10.1016/j.jaci.2007.08.011
Schmitt J, Langan S, Deckert S, Svensson A, von Kobyletzki L, Thomas K, et al. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol 2013; 132: 1337-1347.
https://doi.org/10.1016/j.jaci.2013.07.008 DOI: https://doi.org/10.1016/j.jaci.2013.07.008
Schmitt J, Spuls P, Boers M, Thomas K, Chalmers J, Roekevisch E, et al. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Allergy 2012; 67: 1111-1117.
https://doi.org/10.1111/j.1398-9995.2012.02874.x DOI: https://doi.org/10.1111/j.1398-9995.2012.02874.x
Thomas KS, Apfelbacher CA, Chalmers JR, Simpson E, Spuls PI, Gerbens LAA, et al. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. Br J Dermatol 2021; 185: 139-146.
https://doi.org/10.1111/bjd.19751 DOI: https://doi.org/10.1111/bjd.19751
Chalmers JR, Thomas KS, Apfelbacher C, Williams HC, Prinsen CA, Spuls PI, et al. Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). Br J Dermatol 2018; 178: e332-e341.
Leshem YA, Chalmers JR, Apfelbacher C, Katoh N, Gerbens LAA, Schmitt J, et al. Measuring atopic eczema control and itch intensity in clinical practice: a consensus statement from the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) Initiative. JAMA Dermatol 2022; 158: 1429-1435.
https://doi.org/10.1001/jamadermatol.2022.4211 DOI: https://doi.org/10.1001/jamadermatol.2022.4211
Gabes M, Tischer C, Herrmann A, Howells L, Apfelbacher C. The German RECAP questionnaire: linguistic validation and cognitive debriefing in German adults with self-reported atopic eczema and parents of affected children. J Patient Rep Outcomes 2021; 5: 13.
https://doi.org/10.1186/s41687-021-00285-2 DOI: https://doi.org/10.1186/s41687-021-00285-2
Gabes M, Ragamin A, Baker A, Kann G, Donhauser T, Gabes D, et al. Content validity of the Recap of atopic eczema (RECAP) instrument in Dutch, English and German to measure eczema control in young people with atopic eczema: a cognitive interview study. Br J Dermatol 2022; 187: 919-926.
https://doi.org/10.1111/bjd.21767 DOI: https://doi.org/10.1111/bjd.21767
Onteniente-Gomis MM, Ortiz-Romero PL, Tous Romero F, Salamanca Castro AB, Ortiz de Frutos FJ. Spanish Version of the RECAP questionnaire to assess control of atopic eczema: translation, cultural adaptation, validation, and correlations with other patient-reported outcome measures. Actas Dermosifiliogr 2023; 114: 488-493. DOI: https://doi.org/10.1016/j.ad.2023.05.009
https://doi.org/10.1016/j.ad.2023.02.018 DOI: https://doi.org/10.1016/j.ad.2023.02.018
Howells LM, Chalmers JR, Gran S, Ahmed A, Apfelbacher C, Burton T, et al. Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (RECAP). Br J Dermatol 2020; 183: 524-536.
https://doi.org/10.1111/bjd.18780 DOI: https://doi.org/10.1111/bjd.18780
Simpson E, Eckert L, Gadkari A, Mallya UG, Yang M, Nelson L, et al. Validation of the Atopic Dermatitis Control Tool (ADCT(c)) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol 2019; 19(1): 15.
https://doi.org/10.1186/s12895-019-0095-3 DOI: https://doi.org/10.1186/s12895-019-0095-3
De Vet HC TC, Mokkink LB, Knol DL. Measurement in medicine: a practical guide. New York: Cambridge University Press; 2011.
https://doi.org/10.1017/CBO9780511996214 DOI: https://doi.org/10.1017/CBO9780511996214
Dancey CP, Reidy J. Statistics without maths for psychology. Harlow, UK: Pearson/Prentice Hall; 2007.
Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 2007; 60: 34-42.
https://doi.org/10.1016/j.jclinepi.2006.03.012 DOI: https://doi.org/10.1016/j.jclinepi.2006.03.012
McHorney CA, Tarlov AR. Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res 1995; 4: 293-307.
https://doi.org/10.1007/BF01593882 DOI: https://doi.org/10.1007/BF01593882
Bhanot A, Peters TJ, Ridd MJ. Assessing the validity, responsiveness and reliability of the Recap measure of eczema control. Br J Dermatol 2021; 184: 955-957.
https://doi.org/10.1111/bjd.19709 DOI: https://doi.org/10.1111/bjd.19709
Bhanot A, Vincent R, Peters TJ, Ridd MJ. Validation of the RECap of AtoPic eczema measure of eczema control for use in dermatology clinics. Clin Exp Dermatol 2022; 47: 440-442.
https://doi.org/10.1111/ced.14934 DOI: https://doi.org/10.1111/ced.14934
Howells LM, Chalmers JR, Cowdell F, Ratib S, Santer M, Thomas KS. 'When it goes back to my normal I suppose': a qualitative study using online focus groups to explore perceptions of 'control' among people with eczema and parents of children with eczema in the UK. BMJ Open 2017; 7: e017731.
https://doi.org/10.1136/bmjopen-2017-017731 DOI: https://doi.org/10.1136/bmjopen-2017-017731
Zuberbier T, Orlow SJ, Paller AS, Taieb A, Allen R, Hernanz-Hermosa JM, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006; 118: 226-232.
https://doi.org/10.1016/j.jaci.2006.02.031 DOI: https://doi.org/10.1016/j.jaci.2006.02.031
Zink AGS, Arents B, Fink-Wagner A, Seitz IA, Mensing U, Wettemann N, et al. Out-of-pocket costs for individuals with atopic eczema: a cross-sectional study in nine European countries. Acta Derm Venereol 2019; 99: 263-267.
https://doi.org/10.2340/00015555-3102 DOI: https://doi.org/10.2340/00015555-3102
Mokkink LB, de Vet HCW, Prinsen CAC, Patrick DL, Alonso J, Bouter LM, et al. COSMIN risk of bias checklist for systematic reviews of patient-reported outcome measures. Qual Life Res 2018; 27: 1171-1179.
https://doi.org/10.1007/s11136-017-1765-4 DOI: https://doi.org/10.1007/s11136-017-1765-4
Stuart BL, Howells L, Pattinson RL, Chalmers JR, Grindlay D, Rogers NK, et al. Measurement properties of patient-reported outcome measures for eczema control: a systematic review. J Eur Acad Dermatol Venereol 2021; 35: 1987-1993.
https://doi.org/10.1111/jdv.17335 DOI: https://doi.org/10.1111/jdv.17335
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Yik Weng Yew, Crystal Zhen Yu Phuan, Xiahong Zhao, Laura Howells, Christian J. Apfelbacher
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
